查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433351

全球生物標記臨床階段外包服務市場2023-2030

Global Biomarker Clinical Phase Outsourcing Services Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3個工作天內

價格

全球生物標記臨床階段外包服務市場預計在預測期內（2023-2030年）CAGR為21.3%。藥物開發過程數量的增加以及癌症、心血管疾病和神經系統疾病等慢性疾病盛行率的上升等重要因素促使人們越來越關注用於早期檢測、疾病監測和治療反應評估的生物標記。世界衛生組織 (WHO) 估計每年有 1790 萬人喪生。此外，根據美國癌症協會的數據，2020年全球估計有1,810萬新發癌症病例和990萬癌症死亡病例。據預測，由於吸煙率上升、不良飲食習慣和缺乏運動等因素，未來幾年癌症負擔將會增加。生物標記顯示各種健康或疾病特徵。

區隔市場前景

全球生物標記臨床階段外包服務市場依類型、治療領域和最終用戶進行區隔。根據類型，市場分為預測生物標記、預後生物標記、安全生物標記和替代終點。根據治療領域，市場區隔為腫瘤學、心臟病學、神經學和自體免疫疾病。此外，根據最終用戶，市場分為製藥公司和生技公司。其中，替代端點子區隔市場預計將佔據相當大的市場佔有率。替代終點是具有良好特徵的生物標記的一小部分，具有經過充分評估的臨床相關性。該區隔市場的成長歸因於合約研究人員在開發用於診斷和監測幾種慢性疾病的替代終點方面的投資不斷增加。

預計心臟病學區隔市場將在全球生物標記臨床階段外包服務市場中佔據相當大的佔有率

在治療領域中，心臟病學區隔市場預計將在全球生物標記臨床階段外包服務市場中佔據相當大的佔有率。區隔市場的成長歸因於冠狀動脈疾病、心臟衰竭、瓣膜性心臟病的盛行率不斷增加，以及對冠狀動脈臨床試驗和技術進步的需求不斷成長。英國心臟基金會（BHF）2023年1月公佈的資料報告稱，2021年最常見的心血管疾病包括冠心病（缺血性）心臟病（2019年全球患病率估計為2億）、外周動脈（血管）疾病（1.1億） 、中風（1億）和心房顫動（6000萬）。此外，報告也顯示，北美、歐洲、非洲和中東、拉丁美洲、亞洲和澳洲的心臟病和循環系統疾病盛行率分別為4,800萬、1億、9,800萬、4,800萬和3.4億。

區域展望

全球生物標記臨床階段外包服務市場根據地理位置進一步區隔，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國） 、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於癌症盛行率不斷上升，越來越多的西方製藥公司將其製造活動外包到印度和中國等新興經濟體，預計亞太地區將在全球市場中佔據顯著佔有率。推動亞太地區生物標記臨床階段外包服務市場。

北美地區預計全球生物標記臨床階段外包服務市場將以顯著的CAGR成長

在所有地區中，預計北美在預測期內將以相當大的CAGR成長。市場成長歸因於北美地區心血管疾病數量的增加，預計將對未來幾年臨床試驗市場的成長產生積極影響。根據美國心臟協會 (AHA) 的數據，心血管疾病仍然是美國的首要死因，2020 年導致 928,741 人死亡。美國癌症協會估計，到 2023 年，預計將診斷出超過 190 萬個新癌症病例在美國。預計 2023 年美國將有約 609,820 人死於癌症，即每天約 1,670 人死亡。此外，由於有專門從事生物標記臨床階段外包服務的成熟合約研究組織，例如全球臨床試驗、Caidya、ICON plc 等。由於在臨床研究中引入了多項創新、突破性技術並提供了最先進的基礎設施，該地區正在進行大量心臟病臨床試驗。根據 ClinicalTrials.gov 的數據，截至 2023 年 9 月，約 5,068 個持久性生物標記臨床階段外包服務在美國註冊。

市場參與者展望

服務於全球生物標記臨床階段外包服務市場的主要公司包括 Celerion、Fujirebio Europe NV、ICON plc 和 Parexel International Corp. 等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2023 年 3 月，醫療保健技術公司 Koneksa Health Inc. 擴大了與生命科學諮詢公司 SSI Strategy 的合作，以擴大基於證據的數位生物標記在臨床試驗中的採用。 Koneksa 的數位生物標記解決方案包括一個平台，該平台允許研究贊助商和臨床站點完美地即時匯總來自患者日記、設備、ePRO 和臨床評估的資料，以提供個人健康狀況的完整視圖。

報告涵蓋

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 依區隔
    • 依地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Celerion
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Fujirebio Europe NV
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • ICON plc
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Parexel International Corp.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場區隔

  • 依類型分類的全球生物標記臨床階段外包服務市場
    • 預測性生物標記
    • 預後生物標記
    • 安全生物標記
    • 代理端點
  • 依治療領域分類的全球生物標記臨床階段外包服務市場
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 自體免疫疾病
  • 以最終用途分類的全球生物標記臨床階段外包服務市場
    • 製藥公司
    • 生技公司

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Charles River Laboratories International, Inc.
  • Eurofins Scientific corp.
  • GenScript ProBio Biotech Corp.
  • GHO Capital Partners LLP
  • Laboratory Corporation of America (R) Holdings
  • NorthEast BioAnalytical Laboratories LLC
  • Proteome Sciences plc
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • Zymewire (Division of Lumerate Inc.)
Product Code: OMR2028015

Global Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report by Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, and Surrogate Endpoints), by Therapeutic Area (Oncology, Cardiology, Neurology, and Autoimmune Diseases), and by End-Use (Pharmaceutical Companies and Biotechnology Companies), Forecast Period (2023-2030)

The global biomarker clinical phase outsourcing services market is anticipated to grow at a CAGR of 21.3% during the forecast period (2023-2030). Significant factors including the increasing number of drug development processes, and the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders has led to an increased focus on biomarkers for early detection, disease monitoring, and treatment response assessment. World Health Organization (WHO) estimated 17.9 million lives every year. Furthermore, according to the American Cancer Society, in 2020, there were an estimated 18.1 million new cancer cases and 9.9 million cancer deaths globally. It is projected that the burden of cancer would increase in coming years as a result of factors including the rising rates of smoking, poor eating habits, and inactivity. Biomarkers indicate a variety of health or disease characteristics.

Segmental Outlook

The global biomarker clinical phase outsourcing services market is segmented on the type, therapeutic area, and end-user. Based on the type, the market is sub-segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, and surrogate endpoints. Based on the therapeutic area, the market is sub-segmented into oncology, cardiology, neurology, and autoimmune diseases. Further, based on end-user, the market is bifurcated into pharmaceutical companies and biotechnology companies. Among the type, the surrogate endpoints sub-segment is anticipated to hold a considerable share of the market. Surrogate endpoints are a small subset of well-characterized biomarkers with well-evaluated clinical relevance. The segmental growth is attributed to the increasing investment by contract researchers in developing surrogate endpoints for the diagnosis and monitoring of several chronic ailments.

Cardiology Sub-Segment is Anticipated to Hold a Considerable Share of the Global Biomarker Clinical Phase Outsourcing Services Market

Among the therapeutic area, the cardiology sub-segment is expected to hold a considerable share of the global biomarker clinical phase outsourcing services market. The segmental growth is attributed to the increasing prevalence of coronary artery disease, heart failure, valvular heart disease, coupled with the rising demand for coronary artery clinical trials and technical advancement. The British Heart Foundation (BHF) data published in January 2023 reported that in 2021, the most common cardiovascular conditions includes coronary (ischemic) heart disease (global prevalence estimated at 200 million in 2019), peripheral arterial (vascular) disease (110 million), stroke (100 million) and atrial fibrillation (60 million). Additionally, the report revealed that the prevalence of heart and circulatory diseases was 48 million, 100 million, 98 million, 48 million and 340 million in North America, Europe, Africa and the Middle East, Latin America, and Asia & Australia.

Regional Outlook

Global biomarker clinical phase outsourcing services market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market around the globe, owing to the increasing prevalence of cancers, increasing number of Western pharmaceutical companies outsourcing their manufacturing activities in emerging economies such as India, and China are driving the biomarker clinical phase outsourcing services market in the Asia Pacific.

The North America Region is Expected to Grow at a Significant CAGR in the Global Biomarker Clinical Phase Outsourcing Services Market

Among all the regions, North America is anticipated to grow at a considerable CAGR over the forecast period. The market growth is attributed to the increasing number of cardiovascular disorders across the North America is estimated to positively impact the clinical trials market growth in upcoming years. According to the American Heart Association (AHA), CVDs remains as the leading cause of death in the US, accounted for 928,741 deaths in the year 2020. American Cancer Society, estimated in 2023, over 1.9 million new cancer cases are expected to be diagnosed in the US. Approximately 609,820 deaths from cancer are expected in the US in 2023, which is about 1,670 deaths per day. Additionally, owing to the presence of established contract research organizations specializing in biomarker clinical phase outsourcing services, such as global clinical trials, Caidya, ICON plc, and several others. Owing to the introduction of several innovative, ground-breaking technologies in clinical research and the provision of state-of-the-art infrastructure, numerous clinical trials for heart disorders are being performed across the region. As per Clinicaltrials.gov, as of September 2023, around 5,068 enduring biomarker clinical phase outsourcing services are registered in the US.

Market Players Outlook

The major companies serving the global biomarker clinical phase outsourcing services market include Celerion, Fujirebio Europe NV, ICON plc, and Parexel International Corp., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2023, healthcare technology firm Koneksa Health Inc., expanded collaboration with life sciences consulting firm SSI Strategy to scale evidence-based digital biomarker adoption in clinical trials. The digital biomarker solutions of Koneksa include a platform which allows research sponsors and clinical sites to impeccably aggregate data, in real-time, from patient diaries, devices, ePROs, and clinical assessments, to deliver a complete view of a person's health.

The Report Covers

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global biomarker clinical phase outsourcing services market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Celerion
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Fujirebio Europe NV
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. ICON plc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Parexel International Corp.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Biomarker Clinical Phase Outsourcing Services Market by Type
    • 4.1.1. Predictive Biomarkers
    • 4.1.2. Prognostic Biomarkers
    • 4.1.3. Safety Biomarkers
    • 4.1.4. Surrogate Endpoints
  • 4.2. Global Biomarker Clinical Phase Outsourcing Services Market by Therapeutic Area
    • 4.2.1. Oncology
    • 4.2.2. Cardiology
    • 4.2.3. Neurology
    • 4.2.4. Autoimmune Diseases
  • 4.3. Global Biomarker Clinical Phase Outsourcing Services Market by End-Use
    • 4.3.1. Pharmaceutical Companies
    • 4.3.2. Biotechnology Companies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Charles River Laboratories International, Inc.
  • 6.2. Eurofins Scientific corp.
  • 6.3. GenScript ProBio Biotech Corp.
  • 6.4. GHO Capital Partners LLP
  • 6.5. Laboratory Corporation of America® Holdings
  • 6.6. NorthEast BioAnalytical Laboratories LLC
  • 6.7. Proteome Sciences plc
  • 6.8. Thermo Fisher Scientific Inc.
  • 6.9. WuXi AppTec Co., Ltd.
  • 6.10. Zymewire (Division of Lumerate Inc.)

LIST OF TABLES

  • 1. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL PREDICTIVE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PROGNOSTIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL SAFETY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL SURROGATE ENDPOINTS BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 7. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN NEUROLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN AUTOIMMUNE DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 12. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR PHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 19. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 21. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 22. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL PREDICTIVE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE, 2022 VS 2030 (%)
  • 3. GLOBAL PROGNOSTIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL SAFETY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL SURROGATE ENDPOINTS BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY THERAPEUTIC AREA, 2022 VS 2030 (%)
  • 7. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN ONCOLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 8. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN CARDIOLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 9. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN NEUROLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 10. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN AUTOIMMUNE DISEASES MARKET SHARE, 2022 VS 2030 (%)
  • 11. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022 VS 2030 (%)
  • 12. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR PHARMACEUTICAL COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)